Corticosteroid-resistant Sweet’s syndrome as the first manifestation of myelodysplastic/myeloproliferative neoplasm-unclassifiable:a case report  

作　　者：Lina Pan Jingru Zhang Peng Li Chuanli Zhao Shaolei Zang Min Ji Fei Lu Jingjing Ye Chunqing Zhang Chunyan Ji 

机构地区：[1]Department of Hematology,Qilu Hospital of Shandong University,Jinan,China.

出　　处：《Emergency and Critical Care Medicine》2022年第4期233-238,共6页急危重症医学（英文）

基　　金：the Shandong Provincial Natural Science Foundation(ZR2020MH119,ZR2020MH118);Distinguished Taishan Scholars in Climbing Plan(tspd20210321);National Nature Science Foundation of China(81400118,81700143);the horizontal subject of Shandong University(6010120072).

摘　　要：A middle-aged man was diagnosed with myelodysplastic/myeloproliferative neoplasm-unclassifiable(MDS/MPN-U),with severe and extensive corticosteroid-resistant Sweet’s syndrome(SS)as the first manifestation,with evidence of clinical manifestations,pathological description,and laboratory evaluation.The skin lesions continued to spread despite treatment with systemic corticosteroids but were successfully treated with intravenous immunoglobulin(IVIG).

关 键 词：Case report Corticosteroid-resistant Intravenous immunoglobulin Myelodysplastic/myeloproliferative neoplasmunclassifiable Sweet’s syndrome 

分 类 号：R733.3[医药卫生—肿瘤]